In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 109 for your search:

Drug:  incomplete Freund's adjuvant
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02897, 99-C-0051, CDR0000066963, CCCGHS-NCI-T98-0085, NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682

Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2012-03086, DM 97-325, MDA-DM-97325, NCI-T98-0017, T98-0017, NCT00004918

Vaccine Therapy in Treating Patients With Liver Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000067782, P30CA016042, UCLA-9905003, NCI-H00-0053, NCT00005629

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000378171, UVACC-MEL-41, UVACC-28502, UVACC-HIC-10464, NCT00089219

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000430929, UVACC-HIC-11491, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, Mel 44, NCT00118274

Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2003-007, NCT00145158

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 80
Sponsor: Other
Protocol IDs: FPCR1R2-2, NCT00655785

Novel Peptide Vaccination for Patients With Advanced Prostate Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMU-H21-40-P?/?, NCT01225471

10.

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 29810, NCT01312389

11.

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, NIH WGMCC
Protocol IDs: 030162, 03-C-0162, NCI-5855, CDR0000304438, NCT00062036

12.

Phase II Pilot Study of HER2-Neu Peptide Vaccine in Patients with Recurrent Metastatic Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0118, NCI-T97-0009, T97-0009

13.

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000065915, NCI-98-C-0022, NCI-T97-0088, T97-0088, NCT00019383

14.

Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0023, NCI-T97-0089, T97-0089

15.

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: CDR0000065997, NCI-98-C-0040, NCI-T97-0092, T97-0092, NCT00019396

16.

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 79
Sponsor: NCI, Other
Protocol IDs: CDR0000066084, UVACC-HIC-7621, UVA-HIC-7621, NCI-G98-1389, NCT00003222

17.

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066176 (10M-97-1), LAC-USC-10M971, LAC-USC-FDR001101, NCI-T97-0100, T97-0100, NCT00003274

18.

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000066287, NCI-98-C-0095, NCI-T98-0012, T98-0012, NCT00019487

19.

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066310 (10M-97-3), LAC-USC-10M973, NCI-G98-1432, NCI-T97-0099, T97-0099, NCT00003339

20.

Phase II Randomized Study of gp100-Tyrosinase Peptide Vaccine Using Sargramostim (GM-CSF), Montanide ISA-51, or QS21 as Adjuvant in Patients with Advanced Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98012, NCI-T97-0110, NCT00003362, T97-0110

21.

Phase II Study of Immunization With gp100 Antigen With Endoplasmic Reticulum Insertion Signal Sequence Alone or in Combination With Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0142, NCI-T98-0036, T98-0036

22.

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 980139, 98-C-0139, NCI-98-C-0139, NCI-T97-0081, T97-0081, NCT00019526, NCT00001703

23.

Phase II Randomized Study of Mutated gp100 Melanoma Peptide With High-Dose Interleukin-2 in HLA-A2.1-Positive Patients With Metastatic Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CWG-UIC-T98-0027, NCI-T98-0027, NCT00003568, T98-0027

24.

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000067051, NCI-99-C-0092, NCI-T99-0033, T99-0033, NCT00019721

25.

Phase II Randomized Study of Mutated gp100 Melanoma Vaccine in HLA-A2-Positive Patients With at Least 1 mm Melanoma on Initial Biopsy. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: NCI
Protocol IDs: PPMC-IRB-99-9, NCI-T98-0081, NCT00003895, T98-0081

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map